Scribe Therapeutics continues to advance the development of its CRISPR platform and pipeline
Company was co-founded by Jennifer Doudna, a co-inventor of CRISPR technology
Scribe Therapeutics has completed an oversubscribed $100m Series B financing round to advance the development of its CRISPR platform and pipeline.
Scribe was co-founded by Jennifer Doudna, a co-inventor of CRISPR technology and co-recipient of the 2020 Nobel Prize in Chemistry.
The company’s platform is based on CRISPR technology (also known as CRISPR-Cas9) – CRISPRs are specialised stretches of DNA that can be cut by Cas9 enzymes.
This technology evolved from the natural defence mechanisms of bacteria and archaea, which use RNA and Cas proteins to target and attack viruses and other foreign bodies.